

Maria A Hawkins

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5587273/maria-a-hawkins-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129 papers	2,990 citations	26 h-index	51 g-index
195 ext. papers	3,692 ext. citations	2.9 avg, IF	5.02 L-index

#	Paper	IF	Citations
129	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.. <i>European Journal of Cancer</i> , 2022 , 164, 18-29	7.5	3
128	A Phase II trial of Higher Radiotherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.. <i>BMJ Open</i> , 2022 , 12, e049119	3	0
127	Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. <i>Radiotherapy and Oncology</i> , 2021 , 165, 119-125	5.3	1
126	Patient and Public Involvement Refines the Design of ProtOeus: A Proposed Phase II Trial of Proton Beam Therapy in Oesophageal Cancer. <i>Patient</i> , 2021 , 14, 545-553	3.7	1
125	Stereotactic radiotherapy and oligometastases - AuthorsReply. <i>Lancet Oncology, The</i> , 2021 , 22, e133	21.7	1
124	Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2021 , 16, 95	4.2	2
123	SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021 , 155, 278-284	5.3	0
122	Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". <i>British Journal of Cancer</i> , 2021 , 124, 679-680	8.7	
121	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021 , 154, 60-69	5.3	14
120	Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. <i>European Journal of Cancer</i> , 2021 , 153, 153-161	7.5	1
119	NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch. <i>Antioxidants</i> , 2021 , 10,	7.1	2
118	A decision tool for radiographer-led abdominal image-guided stereotactic ablative body radiotherapy - Experience from a single institution. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021 , 19, 33-36	1.9	
117	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. <i>Radiotherapy and Oncology</i> , 2021 , 164, 104-114	5.3	0
116	Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. <i>Lancet Oncology, The</i> , 2021 , 22, 98-106	21.7	40
115	A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). <i>Radiation Oncology</i> , 2020 , 15, 151	4.2	7
114	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 765-775	18.8	19
113	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020 , 123, 709-713	8.7	13

112	UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. <i>European Journal of Cancer</i> , 2020 , 128, 7-16	7.5	9
111	Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020 , 13, 24-30	1.9	4
110	Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low Δ /ratio. <i>Radiotherapy and Oncology</i> , 2020 , 143, 58-65	5.3	5
109	A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 20, 19-26	4.6	5
108	Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity. <i>Advances in Radiation Oncology</i> , 2020 , 5, 1311-1319	3.3	6
107	NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. <i>Cancer Genetics</i> , 2020 , 248-249, 1-10	2.3	4
106	Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. <i>Radiotherapy and Oncology</i> , 2020 , 151, 280-286	5.3	2
105	The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 604387	5.3	5
104	Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer. <i>Radiotherapy and Oncology</i> , 2020 , 143, 19-23	5.3	9
103	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. <i>Radiotherapy and Oncology</i> , 2020 , 148, 194-200	5.3	34
102	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019 , 21, 387-391	3.9	5
101	Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?. <i>Clinical Oncology</i> , 2019 , 31, 72-80	2.8	6
100	Systematic review and meta-analysis of small bowel dose-volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019 , 138, 38-44	5.3	9
99	Driving developments in UK oesophageal radiotherapy through the SCOPE trials. <i>Radiation Oncology</i> , 2019 , 14, 26	4.2	4
98	Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study. <i>Radiotherapy and Oncology</i> , 2019 , 141, 62-66	5.3	11
97	PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4166-TPS4166	2.2	0
96	Outcomes following stereotactic body radiotherapy (SBRT) in locally recurrent rectal cancer (LRRC) in a previously irradiated pelvis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 640-640	2.2	
95	Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 557-557	2.2	

94	Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). <i>BMC Cancer</i> , 2019 , 19, 121	4.8	6
93	Impact of abdominal compression on setup error and image matching during radical abdominal radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019 , 12, 28-33	1.9	3
92	Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. <i>Cancer</i> , 2018 , 124, 2001-2009	6.4	15
91	Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 1202-1211	4	25
90	A Randomised Trial of Conventional Care versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases. <i>Clinical Oncology</i> , 2018 , 30, e64	2.8	3
89	Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>Clinical Oncology</i> , 2018 , 30, 418-426	2.8	3
88	Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit. <i>Clinical Oncology</i> , 2018 , 30, 280-284	2.8	11
87	UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. <i>Clinical Oncology</i> , 2018 , 30, 5-14	2.8	109
86	Session 3: Beyond the boundaries of Total Mesorectal Excision - where surgeons fear to tread. <i>Colorectal Disease</i> , 2018 , 20 Suppl 1, 61-64	2.1	1
85	SPARC: A phase-I trial of pre-operative margin-intensified stereotactic radiotherapy for pancreatic cancer at high risk of positive resection margins.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS536-TPS536	2.2	
84	CORE: A randomised trial of COventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases. <i>Lung Cancer</i> , 2018 , 115, S85-S86	5.9	2
83	Session 3: Intra-operative radiotherapy - creating new surgical boundaries. <i>Colorectal Disease</i> , 2018 , 20 Suppl 1, 65-75	2.1	
82	Initial Results from the Royal College of RadiologistsRUK National Audit of Anal Cancer Radiotherapy 2015. <i>Clinical Oncology</i> , 2017 , 29, 188-197	2.8	20
81	NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2017 , 74, 38-46	7.5	26
80	The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 51-60	4	42
79	Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data. <i>Radiotherapy and Oncology</i> , 2017 , 123, 431-437	5.3	12
78	Correlation of F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. <i>Clinical Oncology</i> , 2017 , 29, 370-377	2.8	17
77	Four-dimensional Computed Tomography Contouring Variability in Stereotactic Body Radiotherapy of Non-resectable Biliary Tract Cancer. <i>Clinical Oncology</i> , 2017 , 29, e137	2.8	

76	Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review. <i>Radiotherapy and Oncology</i> , 2017 , 125, 213-222	5.3	20
75	Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit. <i>Trials</i> , 2017 , 18, 620	2.8	3
74	Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 729-737	4	13
73	Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. <i>American Journal of Clinical Nutrition</i> , 2017 , 106, 849-857	7	31
72	Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. <i>Frontiers in Oncology</i> , 2017 , 7, 153	5.3	26
71	Stepwise Multicenter Introduction of Intensity Modulated Radiation Therapy for Anal Cancer in the United Kingdom: From Consensus Guidance to Large-Scale Prospective Audit, Prior to Future Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, S105-S106	4	3
70	A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the SPARC trial protocol. <i>BMC Cancer</i> , 2016 , 16, 728	4.8	11
69	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 627-42	19.4	162
68	Intravenous contrast-enhanced cone beam computed tomography (IVCBCT) of intrahepatic tumors and vessels. <i>Advances in Radiation Oncology</i> , 2016 , 1, 43-50	3.3	7
67	On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 119-119	2.2	4
66	NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3-3	2.2	1
65	Salvage surgery with abdominoperineal excision of the rectum (APER) following loco-regional failure after chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) and the impact of lymph node status. Results of a CRT trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3522-3522	2.2	1
64	WE-AB-202-10: Modelling Individual Tumor-Specific Control Probability for Hypoxia in Rectal Cancer. <i>Medical Physics</i> , 2016 , 43, 3796-3796	4.4	
63	SU-D-BRA-06: Duodenal Interfraction Motion with Abdominal Compression. <i>Medical Physics</i> , 2016 , 43, 3340-3340	4.4	
62	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. <i>Oncotarget</i> , 2016 , 7, 12672-81	3.3	32
61	Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2016 , 121, 232-238	5.3	29
60	Unwrapping 3D complex hollow organs for spatial dose surface analysis. <i>Medical Physics</i> , 2016 , 43, 6009	4.4	3
59	ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016 , 119, 306-11	5.3	39

58	An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 199-207	4	22
57	Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016 , 121, 86-91	5.3	9
56	The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, E164-E165	4	30
55	OC-0057: Cardiotoxicity and cardiac substructure dosimetry in doseescalated lung radiotherapy. <i>Radiotherapy and Oncology</i> , 2016 , 119, S24-S25	5.3	2
54	Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT). <i>Radiotherapy and Oncology</i> , 2016 , 121, 92-97	5.3	4
53	Stereotactic body radiotherapy for liver metastases. <i>Clinical Oncology</i> , 2015 , 27, 307-15	2.8	37
52	NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. <i>BMC Cancer</i> , 2015 , 15, 48	4.8	23
51	A tumor control probability model for anal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015 , 116, 192-6	5.3	26
50	Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 246-51	5.3	16
49	The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. <i>Radiation Oncology</i> , 2015 , 10, 236	4.2	4
48	ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC) Mechanism and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15279-e15279	2.2	
47	TH-AB-BRB-11: A Method of Unwrapping 3D Complex Hollow Organs for Spatial Dose Surface Analysis. <i>Medical Physics</i> , 2015 , 42, 3706-3706	4.4	
46	Prospective Review of Outlining in the UK NeoSCOPE Esophageal Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, S733	4	2
45	The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. <i>Clinical Oncology</i> , 2014 , 26, 581-96	2.8	12
44	The role of radiotherapy and chemoradiation in the management of primary liver tumours. <i>Clinical Oncology</i> , 2014 , 26, 569-80	2.8	14
43	Challenges in using 18 F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2014 , 9, 146	4.2	13
42	Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease. <i>Acta Oncologica</i> , 2014 , 53, 702-6	3.2	11
41	Cone beam CT verification for active breathing control (ABC)-gated radiotherapy for lung cancer. <i>Acta Oncologica</i> , 2014 , 53, 716-9	3.2	2

40	Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 423-9	4	29
39	Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability. <i>Radiation Oncology</i> , 2014 , 9, 286	4.2	9
38	Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours. <i>Acta Oncologica</i> , 2014 , 53, 149-54	3.2	1
37	214 A trial in design: CORE II Conventional Care or Radioablation in the treatment of Extracranial metastases. <i>Lung Cancer</i> , 2014 , 83, S79	5.9	9
36	Patient and tumor characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomized phase III ACT II trial: Implications for radiotherapy target volume.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4032-4032	2.2	1
35	NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4144-TPS4144	2.2	1
34	Volumetric analysis of anal cancer relapses following radical chemoradiation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 576-576	2.2	
33	Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. <i>British Journal of Surgery</i> , 2013 , 100, 1009-14	5.3	123
32	Stereotactic body radiotherapy for oligometastases. <i>Lancet Oncology, The</i> , 2013 , 14, e28-37	21.7	326
31	Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. <i>Clinical Oncology</i> , 2013 , 25, 155-61	2.8	28
30	Oesophageal Chemoradiotherapy in the UK--current practice and future directions. <i>Clinical Oncology</i> , 2013 , 25, 368-77	2.8	22
29	Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost. <i>British Journal of Radiology</i> , 2013 , 86, 20120466	3.4	20
28	MO-F-WAB-01: A Comparison of 20 Free Breathing Versus AlignRT Based DIBH Breast Treatments. <i>Medical Physics</i> , 2013 , 40, 409-410	4.4	
27	Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. <i>BMC Cancer</i> , 2012 , 12, 530	4.8	15
26	Effect of anaemia prevention on survival and local control in oesophageal cancers treated with chemoradiotherapy. <i>Clinical Oncology</i> , 2012 , 24, 454-5	2.8	
25	Volumetric modulated arc therapy planning for distal oesophageal malignancies. <i>British Journal of Radiology</i> , 2012 , 85, 44-52	3.4	22
24	Image-guided radiotherapy for esophageal cancer. <i>Imaging in Medicine</i> , 2012 , 4, 515-525	1	1
23	Does phase I radiotherapy dose of 30.6Gy in 17 fractions provide adequate microscopic nodal disease control in squamous cell carcinoma of the anus?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 588-588	2.2	

22	Nonsurgical management of esophageal adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 165-70	3.8	1
21	Set-up errors in radiotherapy for oesophageal cancers--is electronic portal imaging or conebeam more accurate?. <i>Radiotherapy and Oncology</i> , 2011 , 98, 249-54	5.3	29
20	Quantification of organ motion during chemoradiotherapy of rectal cancer using cone-beam computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, e431-8	4	24
19	Cone beam CT verification for oesophageal cancer - impact of volume selected for image registration. <i>Acta Oncologica</i> , 2011 , 50, 1183-90	3.2	14
18	Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 378-83	4	23
17	Dynamic shape instantiation for intra-operative guidance. <i>Lecture Notes in Computer Science</i> , 2010 , 13, 69-76	0.9	12
16	Motion artifact correction in free-breathing abdominal MRI using overlapping partial samples to recover image deformations. <i>Magnetic Resonance in Medicine</i> , 2009 , 62, 440-9	4.4	20
15	Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?. <i>Clinical Oncology</i> , 2009 , 21, 376-9	2.8	18
14	The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. <i>British Journal of Radiology</i> , 2009 , 82, 321-7	3.4	27
13	HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. <i>Breast</i> , 2008 , 17, 661-5	3.6	18
12	Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. <i>Radiotherapy and Oncology</i> , 2008 , 88, 121-6	5.3	14
11	Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 657-64	2.2	446
10	Improving image-guided target localization through deformable registration. <i>Acta Oncologica</i> , 2008 , 47, 1279-85	3.2	42
9	Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. <i>Clinical Oncology</i> , 2008 , 20, 221-6	2.8	35
8	Penile Bulb Dosimetry Impact of Prostate Brachytherapy Implant Technique. <i>Clinical Oncology</i> , 2007 , 19, S7-S8	2.8	2
7	Feasibility of Free-breathing Respiratory Gated Liver Radiotherapy with MRI-derived Models. <i>Clinical Oncology</i> , 2007 , 19, S13	2.8	4
6	Radiation therapy for hepatocellular carcinoma: from palliation to cure. <i>Cancer</i> , 2006 , 106, 1653-63	6.4	196
5	Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 64, 751-9	4	171

4	Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 610-9	4	94
3	Respiratory Gated Cone-Beam CT Volumetric Imaging for External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, S27-S28	4	8
2	Comparison of Breath Hold Cone Beam CT and Orthogonal Image Guided Radiotherapy for Liver Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, S555-S556	4	3
1	Case 23-2005: a man with a mass in the liver. <i>New England Journal of Medicine</i> , 2005 , 353, 2195-7; author reply 2195-7	59.2	